Attracted by the distinctive advantages of BsAb and non-IgG antibodies (mainly IgA, IgM, and IgE), scientists at Creative Biolabs are trying their best to develop potential bispecific non-IgG antibodies in recent years.

Development of BsAb is an extremely fast-growing field with innovative formats emerging constantly. As a senior biotechnology company with strong comprehensive strength, Creative Biolabs endeavors to develop the most comprehensive and the highest quality BsAb service.